Literature DB >> 17472875

Nutrition support in acute pancreatitis.

Stephen A McClave1.   

Abstract

The benefit of early enteral nutrition (EN) for the disease process and for patient outcome in severe acute pancreatitis is dramatic. A narrow window of opportunity exists during which there is potential for EN to decrease disease severity and reduce overall complications. Most patients with severe pancreatitis tolerate enteral feeds. Any signs of symptom exacerbation or increasing inflammation in response to EN may be ameliorated by subtle adjustments in the feeding strategy. In this manner, provision of EN represents primary therapy in the management of the patient with acute pancreatitis and is emerging as the gold standard of therapy in nutrition support for this disease process.

Entities:  

Mesh:

Year:  2007        PMID: 17472875     DOI: 10.1016/j.gtc.2007.01.002

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  3 in total

Review 1.  Acute pancreatitis during pregnancy: a review.

Authors:  G Ducarme; F Maire; P Chatel; D Luton; P Hammel
Journal:  J Perinatol       Date:  2013-12-19       Impact factor: 2.521

2.  Clinical analysis of 16 patients with acute pancreatitis in the third trimester of pregnancy.

Authors:  Yanmei Sun; Cuifang Fan; Suqing Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

3.  Pancreatitis, very early compared with normal start of enteral feeding (PYTHON trial): design and rationale of a randomised controlled multicenter trial.

Authors:  Olaf J Bakker; Hjalmar C van Santvoort; Sandra van Brunschot; Usama Ahmed Ali; Marc G Besselink; Marja A Boermeester; Thomas L Bollen; Koop Bosscha; Menno A Brink; Cornelis H Dejong; Erwin J van Geenen; Harry van Goor; Joos Heisterkamp; Alexander P Houdijk; Jeroen M Jansen; Thom M Karsten; Eric R Manusama; Vincent B Nieuwenhuijs; Bert van Ramshorst; Alexander F Schaapherder; George P van der Schelling; Marcel Bm Spanier; Adriaan Tan; Juda Vecht; Bas L Weusten; Ben J Witteman; Louis M Akkermans; Hein G Gooszen
Journal:  Trials       Date:  2011-03-10       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.